Update information
June 2019: Sections 1 and 2 updated to include a new commercial arrangement. Standard text in implementation section updated.
April 2014: Implementation section updated to clarify that lenalidomide is recommended as an option for treating multiple myeloma in people who have received two or more prior therapies.
ISBN: 978-1-4731-3450-8